Stammdaten
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Unternehmen & Branche
| Name | 20/20 Biolabs, Inc. |
|---|---|
| Ticker | AIDX |
| CIK | 0001139685 |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 7,6 Mio. USD |
| Beta | -0,43 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 2,045,133 | -3,738,821 | -0.76 | 4,137,357 | -19,225 |
| 2024-12-31 | 10-K | 1,752,343 | -5,551,667 | -1.16 | 3,584,408 | 1,505,482 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.